Work

Galectin-3 Is Associated With Risk of Cardiovascular and Kidney Outcomes in Ambulatory Veterans

Year: 2025

Type: article

Abstract: Rationale & Objective: Cardiovascular and kidney disease are highly prevalent comorbid conditions, and each is a risk factor for the other condition. We evaluated whether Galectin-3 (Gal-3), a biomarker of organ fibrosis, is associated with cardiovascular and kidney events in ambulatory Veterans. Study Design: An observational cohort study. Setting & Participants: Ambulatory Veterans presenting for an outpatient echocardiogram at the San Diego Veterans Affairs between 2010 and 2013. Predictor: Blood Gal-3 levels. Outcomes: The primary cardiovascular outcome was major adverse cardiac events (MACEs: acute coronary syndrome [ACS], stroke, heart failure [HF] hospitalization, or cardiovascular death). The primary kidney outcome was major adverse kidney events (MAKEs: ≥40% estimated glomerular filtration rate decrease or renal replacement therapy). Secondary outcomes were cardiovascular death, incident HF, ACS, and all-cause mortality. Analytical Approach: Cox proportional hazard models adjusting for cardiovascular and kidney disease risk factors. Results: = 0.002). Limitations: Select population of Veterans presenting for an echocardiogram who were primarily older men with multiple comorbid conditions. Conclusions: Gal-3 is associated with risk of cardiovascular and kidney outcomes among ambulatory Veterans.

Source: Kidney Medicine

DOI: 10.1016/j.xkme.2025.101089

Authors: Shreya Banerjee, Pranav S. Garimella, Kimberly N. Hong, Alexander L. Bullen, Lori B. Daniels, Nicholas Wettersten

Institutions: University of California San Diego, VA San Diego Healthcare System

Language: English

Topic: Galectins and Cancer Biology

Subfield: Immunology

Field: Immunology and Microbiology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $2,590